On Monday, Shares of Freeport-McMoRan Inc (NYSE:FCX), added 0.59% and closed at $10.19 in the last trading session. The last trading range of the stock ranges between $10.14 and $10.42. The company’s Market capitalization is $13.31 Billion with the total Outstanding Shares of 1.33 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $3.52 and reached to max level of $14.20. Freeport-McMoRan Inc. (FCX) declared recently the expiration of the formerly declared consent solicitations by it and its wholly owned auxiliaries, Freeport-McMoRan Oil & Gas LLC (FM O&G) and FCX Oil & Gas Inc. (FCX O&G). The consent solicitations expired at 5:00 p.m., New York City time, on September 28, 2016. As of the expiration time, FCX, FM O&G and FCX O&G had not received the consent of holders of at least a majority in aggregate principal amount outstanding of each series of notes subject to the consent solicitations. As a result, no consent fees will be paid and FCX plans to merge FM O&G into FCX before concluding its formerly declared Deepwater Gulf of Mexico sale transaction.
FCX is a premier U.S.-based natural resources company with an industry-leading global portfolio of mineral assets. FCX is the world’s leading publicly traded copper producer.
FCX’s portfolio of assets includes the Grasberg minerals district in Indonesia, one of the world’s leading copper and gold deposits; noteworthymining operations in the Americas, counting the large-scale Morenci minerals district in North America and the Cerro Verde operation in South America. Additional information about FCX is available on FCX’s website.
Gilead Sciences, Inc. (NASDAQ:GILD), jumped 0.33% and closed at $75.49 in the last trading session. The last trading range of the stock ranges between $75.26 and $75.97. The company’s Market capitalization is $98.35 Billion with the total Outstanding Shares of 1.32 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $74.92 and reached to max level of $111.11. Gilead Sciences, Inc. (GILD) recently declared it has reached a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis (VL). As part of this collaboration, Gilead will donate 380,000 vials of AmBisome® (amphotericin B liposome for injection) to meet the needs of WHO to treat VL in key endemic countries, counting Bangladesh, Ethiopia, India, Nepal, South Sudan and Sudan.
VL, also known as kala-azar, is the world’s second-deadliest parasitic infectious disease and affects up to 300,000 people annually in resource-limited countries.
“This new partnershipcomes at the right time as we gear up to support endemic countries in the Eastern Africa sub-region and South-East Asia to eliminate visceral leishmaniasis as a public health problem by or before 2020,” said Dr. Ren Minghui, WHO Assistant Director-General for HIV/AIDS, Malaria and Neglected Tropical Diseases. “During the past five years, AmBisome, donated by Gilead, allowed many countries in the Region highly endemic for VL to implement WHO’s recommended first line treatment, benefitting thousands of people.”
Gilead’s support of WHO’s leishmaniasis control program began in 1992. In December 2011, Gilead expanded its partnership by donating about 445,000 vials of AmBisome to treat more than 50,000 people over five years and to expand the number of VL treatment centers from fewer than 15 in 2011 to more than 160 in 2015.